ADMA BIOLOGICS, INC. (ADMA) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US0008991046

Price
11.07 USD
Market cap
2.48 bn USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

ADMA BIOLOGICS, INC. financials

Fiscal year2025
Revenue510.17 m USD
Gross profit292.77 m USD
Operating income191.44 m USD
EBIT187.90 m USD
Net income146.93 m USD
Diluted EPS – continuing operations0.60 USD

Full history since 2006, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About ADMA BIOLOGICS, INC.

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 26.10.2026. Details in the risk notice.